» Articles » PMID: 39004839

Mitochondrial Proteins As Metabolic Biomarkers and Sites for Therapeutic Intervention in Primary and Metastatic Cancers

Overview
Specialty Chemistry
Date 2024 Jul 15
PMID 39004839
Authors
Affiliations
Soon will be listed here.
Abstract

Accelerated aerobic glycolysis is one of the main metabolic alterations in cancer, associated with malignancy and tumor growth. Although glycolysis is one of the most studied properties of tumor cells, recent studies demonstrate that oxidative phosphorylation (OxPhos) is the main ATP provider for the growth and development of cancer. In this last regard, the levels of mRNA and protein of OxPhos enzymes and transporters (including glutaminolysis, acetate and ketone bodies catabolism, free fatty acid β-oxidation, Krebs Cycle, respiratory chain, phosphorylating system- ATP synthase, ATP/ADP translocator, Pi carrier) are altered in tumors and cancer cells in comparison to healthy tissues and organs, and non-cancer cells. Both energy metabolism pathways are tightly regulated by transcriptional factors, oncogenes, and tumor-suppressor genes, all of which dictate their protein levels depending on the micro-environmental conditions and the type of cancer cell, favoring cancer cell adaptation and growth. In the present review paper, variation in the mRNA and protein levels as well as in the enzyme/ transporter activities of the OxPhos machinery is analyzed. An integral omics approach to mitochondrial energy metabolism pathways may allow for identifying their use as suitable, reliable biomarkers for early detection of cancer development and metastasis, and for envisioned novel, alternative therapies.

References
1.
Luo W . Nasopharyngeal carcinoma ecology theory: cancer as multidimensional spatiotemporal "unity of ecology and evolution" pathological ecosystem. Theranostics. 2023; 13(5):1607-1631. PMC: 10086202. DOI: 10.7150/thno.82690. View

2.
Tobore T . On the need for the development of a cancer early detection, diagnostic, prognosis, and treatment response system. Future Sci OA. 2020; 6(2):FSO439. PMC: 6997916. DOI: 10.2144/fsoa-2019-0028. View

3.
Slodkowska E, Ross J . MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn. 2009; 9(5):417-22. DOI: 10.1586/erm.09.32. View

4.
Ozaslan M, Balci N, Demir Y, Gurbuz M, Irfan Kufrevioglu O . Inhibition effects of some antidepressant drugs on pentose phosphate pathway enzymes. Environ Toxicol Pharmacol. 2019; 72:103244. DOI: 10.1016/j.etap.2019.103244. View

5.
Warburg O . On respiratory impairment in cancer cells. Science. 1956; 124(3215):269-70. View